Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'
Tweet Send to a Friend
Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
